Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza

The Journal of infectious diseases

Volumn 221, Issue 3, 2020, Pages 346-355

  Uehara, Takeki ^a   Hayden, Frederick G ^b   Kawaguchi, Keiko ^a   Omoto, Shinya ^a   Hurt, Aeron C ^c   De Jong, Menno D ^d   Hirotsu, Nobuo ^e   Sugaya, Norio ^f   Lee, Nelson ^g   Baba, Keiko ^a   Shishido, Takao ^a   Tsuchiya, Kenji ^a   Portsmouth, Simon ^a   Kida, Hiroshi ^h  

^a SHIONOGI AND CO LTD   (Japan)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Keiyu Hospital ^*  (Japan)

^f Keiyu Orthopedic Hospital   (Japan)

^g UNIVERSITY OF ALBERTA   (Canada)

^h HOKKAIDO UNIVERSITY   (Japan)

Author keywords

antiviral susceptibility; baloxavir marboxil; cap dependent endonuclease; influenza; polymerase acidic protein

Indexed keywords

ANTIVIRUS AGENT; BALOXAVIR; OSELTAMIVIR; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; INFLUENZA; INFLUENZA A VIRUS (H3N2); MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; OXAZINES; PYRIDINES; RISK FACTORS; THIEPINS; TREATMENT OUTCOME; TRIAZINES; VIRAL LOAD; YOUNG ADULT;

EID: 85074969970     PISSN: None     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiz244     Document Type: Article

References (0)